Cargando…

A Phase II, Randomized, Safety and Immunogenicity Study of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults

Two formulations of a new live tetravalent dengue virus (DENV) vaccine produced using re-derived master seeds from a precursor vaccine and that same precursor vaccine as a control were compared in a placebo-controlled, randomized, observer-blind, phase II trial of 86 healthy adults. Two vaccine dose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thomas, Stephen J., Eckels, Kenneth H., Carletti, Isabelle, De La Barrera, Rafael, Dessy, Francis, Fernandez, Stefan, Putnak, Robert, Toussaint, Jean-Francois, Sun, Wellington, Bauer, Kristen, Gibbons, Robert V., Innis, Bruce L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Tropical Medicine and Hygiene 2013
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541749/ https://www.ncbi.nlm.nih.gov/pubmed/23208878 http://dx.doi.org/10.4269/ajtmh.2012.12-0361

Ejemplares similares

Safety and Immunogenicity of a Rederived, Live-Attenuated Dengue Virus Vaccine in Healthy Adults Living in Thailand: A Randomized Trial
por: Watanaveeradej, Veerachai, et al.
Publicado: (2014)

A Phase II, Randomized, Safety and Immunogenicity Trial of a Re-Derived, Live-Attenuated Dengue Virus Vaccine in Healthy Children and Adults Living in Puerto Rico
por: Bauer, Kristen, et al.
Publicado: (2015)

Long-Term Safety and Immunogenicity of a Tetravalent Live-Attenuated Dengue Vaccine and Evaluation of a Booster Dose Administered to Healthy Thai Children
por: Watanaveeradej, Veerachai, et al.
Publicado: (2016)

An Adjuvanted, Tetravalent Dengue Virus Purified Inactivated Vaccine Candidate Induces Long-Lasting and Protective Antibody Responses Against Dengue Challenge in Rhesus Macaques
por: Fernandez, Stefan, et al.
Publicado: (2015)

Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical Trial
por: Martinez, Luis Javier, et al.
Publicado: (2015)

Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions
por: Moris, Philippe, et al.
Publicado: (2019)

Immunological Assays used to Support Efficacy of Zika Virus Vaccines
por: Eckels, Kenneth H., et al.
Publicado: (2019)

Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico
por: Diaz, Clemente, et al.
Publicado: (2018)

Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States
por: Schmidt, Alexander C., et al.
Publicado: (2017)

Cell-Mediated Immunity Generated in Response to a Purified Inactivated Vaccine for Dengue Virus Type 1
por: Friberg, Heather, et al.
Publicado: (2020)

Recombinant Dengue 2 Virus NS3 Helicase Protein Enhances Antibody and T-Cell Response of Purified Inactivated Vaccine
por: Simmons, Monika, et al.
Publicado: (2016)

Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody
por: Trirawatanapong, Thaweesak, et al.
Publicado: (1992)

Dengue Virus Exposures Among Deployed U.S. Military Personnel
por: Hesse, Elisabeth M., et al.
Publicado: (2017)

Safety and Immunogenicity of an AS03(B)-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized Study
por: Lin, Leyi, et al.
Publicado: (2020)

Dengue conundrums()
por: Gibbons, Robert V.
Publicado: (2010)

Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I Study
por: Diaz, Clemente, et al.
Publicado: (2020)

Enhanced Immunogenicity of Inactivated Dengue Vaccines by Novel Polysaccharide-Based Adjuvants in Mice
por: Wu, Shuenn-Jue, et al.
Publicado: (2022)

Rational Design of a Live Attenuated Dengue Vaccine: 2′-O-Methyltransferase Mutants Are Highly Attenuated and Immunogenic in Mice and Macaques
por: Züst, Roland, et al.
Publicado: (2013)

Correction: Rational Design of a Live Attenuated Dengue Vaccine: 2′-O-Methyltransferase Mutants Are Highly Attenuated and Immunogenic in Mice and Macaques
por: Züst, Roland, et al.
Publicado: (2013)

Impact of prior Dengue immunity on Zika vaccine protection in rhesus macaques and mice
por: Larocca, Rafael A., et al.
Publicado: (2021)

The re-emergence of dengue in China
por: Ooi, Eng Eong
Publicado: (2015)

Evaluation of potential immunogenicity differences between Pandemrix™ and Arepanrix™
por: Canelle, Quentin, et al.
Publicado: (2016)

Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City
por: Biswal, Shibadas, et al.
Publicado: (2021)

In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination
por: Whitehead, Stephen S., et al.
Publicado: (2017)

COVID-19 mRNA Vaccines Preserve Immunogenicity after Re-Freezing
por: Grau, Santiago, et al.
Publicado: (2022)

Dengue Viral RNA Levels in Peripheral Blood Mononuclear Cells Are Associated with Disease Severity and Preexisting Dengue Immune Status
por: Srikiatkhachorn, Anon, et al.
Publicado: (2012)

636. A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Quadrivalent Dengue Vaccine (V181)
por: Russell, Kevin, et al.
Publicado: (2021)

Comparative immunogenicity of preparations of yeast-derived dengue oral vaccine candidate
por: Bal, Jyotiranjan, et al.
Publicado: (2018)

Development of MVA-d34 Tetravalent Dengue Vaccine: Design and Immunogenicity
por: Mintaev, Ramil R., et al.
Publicado: (2023)

Clinical Efficacy, Safety, and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine (CYD-TDV) in Children: A Systematic Review with Meta-analysis
por: Malisheni, Moffat, et al.
Publicado: (2017)

Polytopic vaccination with a live-attenuated dengue vaccine enhances B-cell and T-cell activation, but not neutralizing antibodies
por: Hunsawong, Taweewun, et al.
Publicado: (2017)

Comparison of real-time SYBR green dengue assay with real-time taqman RT-PCR dengue assay and the conventional nested PCR for diagnosis of primary and secondary dengue infection
por: Paudel, Damodar, et al.
Publicado: (2011)

Incomplete Protection against Dengue Virus Type 2 Re-infection in Peru
por: Forshey, Brett M., et al.
Publicado: (2016)

Safety and Immunogenicity of a Tetravalent Dengue DNA Vaccine Administered with a Cationic Lipid-Based Adjuvant in a Phase 1 Clinical Trial
por: Danko, Janine R., et al.
Publicado: (2018)

Evaluation of Cardiac Involvement in Children with Dengue by Serial Echocardiographic Studies
por: Kirawittaya, Tawatchai, et al.
Publicado: (2015)

Choroidal Neovascularization Induced by Immunogenic Alteration of the Retinal Pigment Epithelium in Dengue Fever
por: Veloso, Carlos Eduardo, et al.
Publicado: (2015)

Dengue virus type-3 envelope protein domain III; expression and immunogenicity
por: Fahimi, Hossein, et al.
Publicado: (2014)

Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo
por: Gorry, Paul R, et al.
Publicado: (2007)

Dengue and US Military Operations from the Spanish–American War through Today
por: Gibbons, Robert V., et al.
Publicado: (2012)

Structural Re-Alignment in an Immunogenic Surface Region of Ricin A Chain
por: Zemla, Adam T., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_vbm4m5l7smn23uvua4ra75mtht